Skip to main content
. 2000 Nov;122(2):264–269. doi: 10.1046/j.1365-2249.2000.01358.x

Table 1.

Clinical features of JCA and RA patients

Samples Age at operation in years Sex RF Diagnosis Medication Synovial pannus cells
JCA
 G 12 13 m 0 JCA (systemic) CyA, Pred,SSZ, NSAID fr
 G 16 3 m 0 JCA (systemic) Pred, SSZ, NSAID fr
 G/Z 26 12 m 0 JCA (systemic) Pred, SSZ fr/c
 G 1 2 f 0 JCA (poly) MTX, NSAID fr
 G 10 9 f 0 JCA (poly) Pred, Gold fr
 G 11 12 m 0 JCA (poly) MTX, Pred, SSZ fr
 G 20 13 f 0 JCA (poly) Pred, NSAID fr
 G 22 7 m + JCA (poly) Pred, SSZ fr
 G 2 14 m 0 JCA (pauci), iridocyclitis Pred, SSZ fr
 G 7 20 m + JCA(pauci) Pred, SSZ, NSAID fr
 G 14 15 f (+) JCA (pauci) SSZ, NSAID fr
 G 23 11 f + JCA (pauci) Pred, SSZ, NSAID fr
 G 25 7 m 0 JCA (pauci) SSZ fr
 G 44 14 m + JCA/psoriasis Pred, SSZ fr
 G 48 10 f 0 JCA/tendovaginitis NSAID c
 G 24 6 m 0 JCA/sarcoidosis Leukeran, NSAID, Pred fr
RA
 G/Z 4 61 f 0 RA + SLE Pred, Azathioprin fr/c
 G/Z 5 70 f + RA Pred, Tauredon, NSAID fr/c
 G 9 71 f + RA MTX, Pred, NSAID fr
 G 13 40 f + RA Azathioprin fr
 G 15 41 f + RA SSZ fr
 G 17 61 f + RA Azathioprin, NSAID fr
 G 21 27 f 0 RA SSZ, Tauredon, NSAID fr
 G 28 58 f 0 RA Chloroquine fr
 G 31 34 f (+) RA MTX, Pred, NSAID fr
 G 32 62 f + RA Pred fr
 G 36 64 f 0 RA MTX, Pred fr
 G 37 63 f + RA MTX, Pred fr
 G 46 76 f + RA Predni, Azathioprin fr
 G 47 65 f (+) RA Predni, Endoxan fr
 G 49 53 m 0 RA MTX, Pred, NSAID fr

Poly, polyarticular onset; pauci, pauciarticular course; systemic, systemic course; SLE, systemic lupus erythematosus; RF, rheumatic factor; Pred, prednison; MTX, methotrexate; NSAID, nonsteroidal anti-inflammatory drugs; SSZ, sulphasalazine; fr, frozen tissue; c, culture of synovial fibroblast cells; +, positive; (+), weak positive; 0, negative.